Adam Bonislawski

1 month ago | genomeweb.com | Adam Bonislawski

NEW YORK — With the recent launch of its Omni 1000 product, Nomic Bio is counting on its low price point and high throughput to help it carve out a market within the protein biomarker discovery space.

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – With its recent decision to discontinue the Clinical Laboratory Improvement Advisory Committee (CLIAC), the US Department of Health and Human Services (HHS) has shut down one of the laboratory industry's main conduits for providing the agency feedback on the functioning of the CLIA program.

1 month ago | genomeweb.com | Adam Bonislawski

NEW YORK – Seer reported first quarter revenues of $4.2 million after the close of market on Tuesday, up 35 percent from $3.1 million in the year-ago period. For the three months ended March 31, the Redwood City, California-based proteomics technology firm posted $2.9 million in product revenue, up 71 percent from $1.7 million a year ago. Service revenue totaled $1.2 million, up nearly threefold from $408,000 in Q1 2024, while other revenue was $60,000, up 67 percent from $36,000 a year ago.

1 month ago | 360dx.com | Adam Bonislawski

NEW YORK – Citing tariffs, cuts to academic funding, and lower biopharma spending, Quanterix on Monday lowered its full-year 2025 revenue guidance to between $120.0 million and $130.0 million.

1 month ago | genomeweb.com | Adam Bonislawski

NEW YORK – Citing tariffs, cuts to academic funding, and lower biopharma spending, Quanterix on Monday lowered its full-year 2025 revenue guidance to between $120.0 million and $130.0 million. The guidance, which excludes revenue from its Lucent Diagnostics business and the expected acquisition of Akoya Biosciences, would represent a year-over-year decline of 5 percent to 13 percent.